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Abstract
Two cardinal manifestations of viral immunity are efficient clearance of acute infection and the capacity to vaccinate against
secondary viral exposure. For noroviruses, the contributions of T cells to viral clearance and vaccination have not been
elucidated. We report here that both CD4 and CD8 T cells are required for efficient clearance of primary murine norovirus
(MNV) infection from the intestine and intestinal lymph nodes. Further, long-lasting protective immunity was generated by
oral live virus vaccination. Systemic vaccination with the MNV capsid protein also effectively protected against mucosal
challenge, while vaccination with the capsid protein of the distantly related human Lordsdale virus provided partial
protection. Fully effective vaccination required a broad immune response including CD4 T cells, CD8 T cells, and B cells, but
the importance of specific immune cell types varied between the intestine and intestinal lymph nodes. Perforin, but not
interferon gamma, was required for clearance of MNV infection by adoptively transferred T lymphocytes from vaccinated
hosts. These studies prove the feasibility of both mucosal and systemic vaccination against mucosal norovirus infection,
demonstrate tissue specificity of norovirus immune cells, and indicate that efficient vaccination strategies should induce
potent CD4 and CD8 T cell responses.
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Introduction
More than 90% of epidemic nonbacterial gastroenteritis
worldwide can be attributed to human noroviruses (HuNV) [1–
3]. Infection is transmitted fecal-orally, and symptomatic infection
is characterized by nausea, vomiting and/or diarrhea lasting 24–
48 hours within 24 hours of exposure [4]. Despite the significant
costs and morbidity of HuNV infections, no vaccine is currently
available. The elderly and individuals in long-term care facilities
may be more susceptible to either norovirus infection or norovirus-
induced disease [5] and would be an important target population
for a norovirus vaccine. The reasons for increased incidence and/
or susceptibility to HuNV disease are unknown. This is due in part
to our incomplete understanding of norovirus immunity. The
potential to vaccinate against these and related viruses has been
demonstrated in gnotobiotic piglets, cats and rabbits [6–8], but the
immune mechanisms responsible have not been identified. The
challenges for vaccine efficacy may be very different between
different caliciviruses. For example, variation in MNV strains is
significantly less than between HuNV strains [9]. Human
volunteer studies demonstrate short-term, but not long-term,
protection against homologous, but not heterologous, viral
challenge [10–12]. Since HuNV belong to 3 genogroups (GI,
GII and GIV) with many strains in each genogroup [4], this lack of
cross-protection is a challenge for vaccine development. Frequent
exposure to noroviruses within short time periods stimulates
sustained immunity and resistance to norovirus induced illness
[13,14]. Serum antibody levels in adults reflect susceptibility to
infection and do not always correlate with protection [13,14]. In
children, however, serum antibody levels correlate with protection,
likely reflecting short-term immunity and recent exposure [15–17].
A nonfunctional fucosyl transferase gene (FUT2) accounts for a
significant proportion, though not all, of resistance to Norwalk
virus infection, suggesting that other factors, yet undiscovered,
may contribute to norovirus resistance [18,19].
In the absence of a cell culture system for HuNV, virus like
particles (VLPs) that assemble when the viral capsid protein is
expressed have been important for evaluating norovirus immune
responses [20–23]. Studies using Norwalk Virus (GI), Snow
Mountain Virus (GII) and HuNoV-HS66 (GII) VLPs to evaluate
immunity after infection with live virus or immunization with VLPs
orally show production of T cell effector cytokines such as IL-2 and
interferon c (IFN-c) and proliferation of norovirus specific T cells
after in vitro restimulation with VLPs [24–26]. These studies show
that T cell responses develop, but do not define their role in either
clearance of primary infection or resistance to re-challenge.
PLoS Pathogens | www.plospathogens.org 1 December 2008 | Volume 4 | Issue 12 | e1000236Together, they suggest the potential for vaccination, but leave open
important questions about the effectiveness and longevity of vaccine
immune responses, mechanisms of vaccination, the viral protein
targetsforprotectiveresponses,andthepotentialforcross-protection
between distantly related noroviruses.
The identification of the first murine norovirus, MNV, and its
propagation in cultured cells provides a facile animal model for
studies of norovirus immunity and pathogenesis [27,28]. MNV, an
enteric virus that infects tissues of the gastrointestinal tract, is
spread by the fecal-oral route ([27] and unpublished studies). The
MNV genome encodes four open reading frames. ORF1 encodes
a polyprotein that is cleaved into individual non-structural proteins
similar to the polyprotein of HuNV [29]. ORF2 encodes the major
capsid protein VP1 and ORF3 encodes a minor capsid protein.
The existence of a protein product for ORF4 has not been
confirmed. In the MNV virion structure, the capsid, like that of
human noroviruses, consists of 90 dimers of VP1 [30]. There are
differences between the MNV virion and previously reported VLP
structures. The MNV protruding domain is lifted off the shell
domain by approximately 16 Angstroms and rotated approxi-
mately 40 degrees in a clockwise fashion, forming interactions at
the P1 base in an infectious virion that have not been observed
previously. The existence of these novel aspects of the structure are
consistent with the hypothesis that MNV may undergo a capsid
maturation process [30].
Studies of MNV pathogenesis reveal an important role for
interferon (IFN) and STAT-1 mediated innate immunity in
resistance to infection and MNV induced lethality [27,31]. The
importance of adaptive immunity in control of MNV infection is
indicated by the observation that RAG1-/- mice develop
persistent MNV infection while wild type (WT) mice can clear
infection with some strains of MNV [9,27,31].
While MNV is an efficient enteric virus that infects many mice
in research mouse colonies around the world, diarrhea has not
been reported after MNV infection. Thus, MNV provides an
infection only model for HuNV infection. Viral titers in tissues of
infected mice have not been reported to exceed 10
6 PFU/ml, and
this highest level of viral titer is obtained after infection of highly
susceptible STAT1-/- mice [31]. In RAG1-/- mice and WT mice,
viral titers of 10
2 to 10
4 PFU/ml are routinely observed [9,31].
The availability of a plaque assay for MNV allows the analysis of
MNV infection despite these low titers. Some MNV strains persist
at a low level in WT mice, while others are cleared from intestine,
spleen, liver, mesenteric lymph nodes (MLN) and feces within 7
days of infection [9,27,31]. Additionally, in wild type C57BL6/J
mice MNV replicates maximally in the distal ileum [9], in
comparison to wild type 129S6/SvEvTac mice where replication
occurs in the proximal intestine [31]. The significance of these
differences is not known.
Studies of norovirus infection in human volunteers have not
specifically investigated whether the infection spreads beyond the
intestine to the local lymph nodes, however, it is possible that
systemic invasion occurs in humans with chronic conditions or
immunosuppressed hosts [32–36]. Additionally, viremia has been
reported in infections of gnotobiotic pigs and calves [26,37,38].
Thus, the ability of MNV to spread to tissues other than the intestine
after oral infection may not be unique, but the relationship of this
aspect of MNV pathogenesis to human infection is not clear. The
availability of strains that can be cleared from WT mice, such as
MNV1.CW3, provides an opportunity to define the mechanisms
responsiblefortwocardinalaspectsofviralimmunity:thecapacityto
effectively clear acute infection and the immune mechanisms
responsible for effective vaccination.
B cells and MNV specific antibody are important in the clearance
of primary MNV infection [39], but the role of T cells in clearance
and the potential and mechanisms of vaccination against mucosal
norovirus challenge are unknown. We show here that vaccination
with either live MNV or Venezuelan Equine Encephalitis replicon
particles (VRPs)expressing the MNV capsidproteinVP1 protect the
intestine against re-challenge for at least six months. Live virus was
more effective than VRP-mediated vaccination. There was partial
cross protection against MNV infection after vaccination with a
HuNV capsid protein. We found that both the clearance of primary
infection and vaccination require the concerted efforts of CD4 T
cells, CD8 T cells, B cells, and that T cells required the effector
molecule perforin for maximal impact on MNV infection. The
effects of specific immune cell types were tissue specific, differing
between ileum and mesenteric lymph nodes. These are the first
studies to demonstrate immune mechanisms responsible for
norovirus clearance and vaccination.
Results
Short-Term Live Virus and Subunit Vaccination against
MNV
We first determined whether we could detect short-term
immunity to homologous MNV challenge and whether proteins
encoded by specific MNV ORFs could elicit effective immunity.
VRPs expressing ORF1, ORF2 and ORF3 of MNV1.CW3 and
ORF2 of the HuNV Lordsdale (genogroup GII.4) and Chiba
(genogroup GI.4) were produced for vaccination experiments.
Western blots of VRP-infected cell lysates revealed proteins of
appropriate sizes [29,40] and additionally showed that hyper-
immunepolyclonal rabbitantisera toMNV [28] cross-reactedatlow
levels with VLPs from Chiba virus and Lordsdale virus (Figure S1A).
WT mice were vaccinated and boosted three weeks later. Two
weeks after boosting, mice were challenged with MNV1.CW3 and
organs titered for MNV three days later (Figure 1A). In these WT
mice, maximal MNV replication in the intestinal tract occurs in the
distal ileum [9] and viral titers could not be detected in duodenum/
jejunum (data not shown). After oral inoculation with MNV1.CW3,
WT mice exhibit detectable viral titers in the distal ileum and the
MLN three to five days post-infection [9,31]. Prior infection with
Author Summary
Human noroviruses are the most common cause of
epidemic nonbacterial gastroenteritis in the world. Despite
their importance as human pathogens, little is known
about how the immune system controls and clears
norovirus infection, and the potential and mechanisms of
vaccination remain unclear. Here, we used norovirus
infection of mice to show that vaccination can provide
long-lasting immunity against mucosal norovirus chal-
lenge and to identify the types of immune cells that are
important in vaccination against norovirus infection.
Similarly, we identified the types of immune T cells that
are important for clearance of acute infection. Efficient
vaccination required all three major arms of adaptive
immunity: CD4 T cells, CD8 T cell, and B cells. Importantly,
protective vaccination against mucosal challenge was
observed after either mucosal or systemic norovirus
antigen exposure. The pore-forming molecule perforin
was important for T cell-mediated control of norovirus
infection. Our study has important implications for
understanding adaptive immunity to norovirus infection,
and may provide insight into the directions to take in
developing a human norovirus vaccine.
Mechanims of Norovirus Immunity
PLoS Pathogens | www.plospathogens.org 2 December 2008 | Volume 4 | Issue 12 | e1000236Figure 1. Short-term vaccination against MNV using live MNV strains and VRPs expressing ORF1, ORF2, and ORF3 from MNV and
ORF2 from Chiba virus and Lordsdale virus. (A) Vaccination protocol used in short-term vaccination. Viral titers in (B) distal ileum and (C) MLN of
adult (8-week-old) WT mice after MNV1.CW3 challenge following vaccination with the indicated vaccines. Viral titers in (D) distal ileum and (E) MLN of
adult (8-week-old) or aged (14-month-old) WT mice immunized with MNV1.CW3 ORF2 VRP or HA VRP and challenged with MNV1.CW3. These data
are pooled from two independent experiments with 3-5 mice per group in each experiment. (**) indicates p,0.0001, (*) indicates p,0.05. Unless
otherwise stated, live virus vaccinations are compared to vaccination with reovirus, and VRP vaccinations are compared to HA VRP. LD indicates the
limit of detection. Bars indicate the arithmetic mean.
doi:10.1371/journal.ppat.1000236.g001
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significantly decreased MNV1.CW3 replication in the distal ileum
compared to control mice infected with reovirus (Figure 1B). Similar
decreases were observed in the MLN after vaccination with
MNV1.CW1 (p=0.0001) or MNV1.CW3 (p=0.0003) (Figure 1C)
compared to the reovirus controls. Similar results were observed in
the spleen (data not shown). There was no statistically significant
difference between vaccination with MNV1.CW1 or MNV1.CW3.
This demonstrates that a protective secondary immune response
develops after clearance of primary MNV infection.
ORF2 VRPs protected against MNV1.CW3 in both distal
ileum (p=0.005) and MLN (p=0.02) compared to control VRPs
expressing hemagglutinin (HA) from a mouse adapted influenza A
virus [41] (HA VRP control group). Controls for VRP vaccination
also included PBS. HA VRP controls were not significantly
different from PBS controls across all experiments and statistical
comparisons for VRP vaccination are therefore shown to HA VRP
controls. ORF1 VRPs alone in the distal ileum, or in both the
distal ileum and MLN when combined with ORF3 VRPs, had a
small but statistically significant effect on MNV1.CW3 levels
(Figure 1B and 1C). ORF3 VRPs alone did not confer significant
protection (Figure 1B and 1C). Together these data show that
vaccination with either live virus or ORF2 VRPs can confer short-
term protection against MNV challenge.
We next assessed vaccination with heterologous ORF2 proteins.
Mice were vaccinated and boosted with VRPs expressing ORF2
from Chiba Virus or Lordsdale virus and challenged with
MNV1.CW3. Vaccination with Lordsdale virus capsid led to
statistically significant protection against MNV infection in the distal
ileum, (p=0.0007, Figure 1B) but not the MLN (Figure 1C). No
significant reduction in MNV titers was seen after immunization
with Chiba virus capsid (Figure 1B and 1C). Protection after
Lordsdale ORF2 VRP vaccination did not correlate with generation
of cross-reactive serum IgG in these mice, measured by ELISA,
despitethepotentialforsuchcross-reactivityrevealedbywesternblot
(Figure S1B). Fecal extracts from immunized mice yielded no
measurable homotypic or heterotypic IgG or IgA (data not shown).
Taken together, these data show that there is measurable functional
immunologic cross protection between Lordsdale virus and MNV in
the distal ileum. The lack of a correlation between serum or fecal
antibody responses and protection suggested that protection may be
T cell mediated.
Vaccination Can Occur in Aged Mice
Since older adults may be more susceptible than younger adults to
norovirus infection or disease [5], we determined whether increased
age altered vaccine efficacy. Prior work has shown that mice older
than 1 year of age have diminished vaccine responses to SARS virus
antigens [42]. We therefore compared vaccine efficacy in adult (8
week old) and aged (14 month old) mice. Adult and aged mice were
vaccinated and challenged as before. In contrast to studies using
SARSvirus antigens [42], aged miceresponded as well as adult mice
to MNV ORF2 vaccination in both the distal ileum and MLN
(Figure 1D and 1E). Despite this protective effect, sera from
vaccinated aged mice had significantly lower anti-MNV ORF2 IgG
compared to adult mice (Figure S1C). These data indicated that
protection against MNV infection occurred in the absence of robust
serologic responses, again raising the possibility that T cells play a
fundamentally important role in vaccination against MNV.
Protective Effect of Live MNV Vaccine Was Sustained over
Six Months
We next determined whether protection conferred by
MNV1.CW3 or MNV ORF2 VRPs was long lived. WT mice were
primed and boosted as shown in Figure 2A with MNV1.CW3 or
MNV ORF2 VRPs. Mice were then challenged with MNV1.CW3
two, four, 14, or 24 weeks later and MNV titers measured three days
post-challenge. Two weeks post-boost, we observed complete
protection against ileal MNV1.CW3 infection after vaccination with
either MNV1.CW3 (p=0.0001) or ORF2 VRPs (p,0.0001)
compared to reovirus or HA VRP controls (Figure 2B). At two
weeks, while vaccination with either MNV1.CW3 or ORF2 VRPs
limited MNV1.CW3 replication in MLN, live virus vaccination was
more effective (p,0.0001) (Figure 2C). Live virus vaccination
conferredfullprotection againstMNV1.CW3replication inboth the
distal ileum and the MLN at four, 14 and 24 weeks after vaccine
boost. Vaccination with ORF2 VRPs was also protective, albeit less
effective than vaccination with MNV1.CW3 (Figure 2B and 2C).
Thus both live virus and subunit vaccine induce long-term
protection against MNV infection, with live virus vaccination
providing more complete protection.
Mechanisms Responsible for Vaccination by Live Virus
and ORF2 VRPs
We next determined the mechanism(s) responsible for effective
vaccination. We vaccinated mice lacking both major histocom-
patibility complex (MHC) Class I and b2 microglobulin (b2M)
[43] (CD8 T cells deficiency [44]), MHC Class II (CD4 T cells
deficiency [45]), or B cell deficient mice [46] (Figure 3A). These
experiments were conducted concurrently with the experiments in
Figure 2 above, as such the data from WT mice are repeated in
the figure for comparison. Live MNV vaccination induced
significant protection against MNV challenge in both the distal
ileum and the MLN of B cell-/-, MHC Class II-/- and MHC
Class I6b2M-/- mice (p,0.05 in all cases, Figure 3B and 3C).
However, there was considerable variation in the efficacy of
vaccination in distal ileum and MLN between different immuno-
deficient strains. In B cell-/- mice, after vaccination with live virus,
only 2 out of 15 mice had any titer (and those two mice had less
than 100 PFU of MNV) and in MHC Class I6b2M-/- mice,
similar vaccination led to undetectable viral titers in the distal
ileum (Figure 3B) but detectable titers in the MLN (Figure 3C). In
MHC Class II-/- mice, there were detectable titers in both tissues
(Figure 3B and 3C). Results for ORF2 vaccination showed that
protection required the activity of all major aspects of the adaptive
immune response (Figure 3B and 3C). Moreover, there was no
protection elicited by ORF2 vaccination in either intestine or
MLN tissue after vaccination of MHC Class I6b2M-/- mice with
ORF2 VRPs (Figure 3B and 3C) indicating that protection by
VRPs critically depends on CD8 T cells. These data demonstrated
that complete protection in all tissues after vaccination with live
virus required the concerted actions of B cells, MHC Class II,
MHC Class I and b2M. Further, the results were consistent with
tissue specific roles for B cells, CD4 T cells and CD8 T cells in the
development of complete protection against MNV infection.
CD8 and CD4 T Cells Are Important for Clearance of
Primary MNV Infection
We next determined whether the same cell types that were
required for vaccination were also required for efficient clearance
of acute infection. We focused on the role of T cells in clearance
since the role of B cells in clearance has already been
demonstrated [39]. To determine the role of T cells in clearance
of acute MNV infection we inoculated WT, MHC Class II-/-, and
MHC Class I6b2M-/- mice orally with MNV1.CW3 and
measured viral titers in the distal ileum and MLN three, five,
seven and 21 days post-infection (Figure 4B–4E).
Mechanims of Norovirus Immunity
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Class I6b2M-/-mice and WT mice at three and five days post-
infection, indicating that MHC Class I and b2M were not
required in MNV infection at early time points (Figure 4B and
4C). However, at seven days post-infection, MHC Class
I6b2M-/- mice had significant levels of MNV titers in both the
distal ileum (p=0.0002) and the MLN (p,0.0001) compared to
WT mice, which had completely cleared the infection (Figure 4B
and 4C). MHC Class I6b2M-/- mice eventually cleared MNV
infection, demonstrated by the lack of viral titers at 21 days post-
infection. Thus, MHC Class I and b2M, and by inference CD8 T
cells were important for efficient clearance of MNV, but were not
required for eventual clearance of MNV infection.
In contrast to MHC I6b2M-/- mice, MHC Class II-/- mice
had higher MNV titers in the ileum than WT mice both three
(p=0.0002) and five (p=0.0058) days after infection (Figure 4D).
At seven days post-infection, minimal viral titers remained and by
eight days post-infection, both MHC Class II-/- and WT mice had
cleared the infection from the distal ileum. In MLN, viral titers in
WT and MHC Class II-/- were not significantly different at days
three and five post-infection. However, there was a small, but
statistically significant increase in titer in the MLN of MHC Class
Figure 2. Long-term vaccination against MNV using a live MNV strain and ORF2 VRPs. (A) Vaccination protocol used in long-term
vaccination. Viral titers in (B) distal ileum and (C) MLN of WT mice after MNV1.CW3 challenge following vaccination with indicated vaccines. These
data are pooled from three independent experiments with 3–5 mice per group in each experiment. (**) indicates p,0.0001, (*) indicates p,0.05.
Unless otherwise stated, live virus vaccinations are compared to vaccination with reovirus, and VRP vaccinations are compared to HA VRP. LD
indicates the limit of detection.
doi:10.1371/journal.ppat.1000236.g002
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Figure 4E). By eight days post-infection, MLN infection was
cleared. Together these data indicated that MHC Class II, and by
inference CD4 T cells, were necessary for control of acute MNV
infection but are not required for eventual clearance of MNV
infection.
To exclude the possibility that the phenotypes we observed in
MHC Class I6b2M-/- and MHC Class II-/- mice were due to
abnormal immune ontogeny in knockout mice, we determined the
requirement for CD4 and CD8 T cells in the clearance of primary
MNV infection in WT mice depleted of CD4 and CD8 T cells.
Depletion of CD4 and CD8 T cells was at least 90% effective as
assessed by flow cytometry of isolated splenocytes (Figure 5A) and
this depletion protocol is effective at depleting T cells in secondary
lymphoid organs and the intestine [47,48]. In comparison to
control antibody, depletion of CD4 T cells, led to a significant
increase in MNV titers in the distal ileum (p=0.0053, Figure 5B),
but not the MLN (Figure 5C). In contrast, depletion of CD8 T
cells led to an increase in MNV titers in both the distal ileum
(p=0.004, Figure 5B), and the MLN (p=0.0025, Figure 5C).
Together, these data from primary challenges of non-immune
mice lacking antigen presenting molecules or depleted of specific T
cell subsets demonstrated that CD4 T cells are important for
efficient MNV clearance in the distal ileum especially at days three
Figure 3. Complete short-term protection against MNV infection requires MHC Class II, MHC Class I, b2M, and B cells. (A) Vaccination
protocol used in short-term vaccination using immunodeficient mice. Viral titers in (B) distal ileum, (C) MLN of B cell-/, MHC Class II-/-, and MHC Class
I6b2M-/- mice after MNV1.CW3 challenge following short-term vaccination with the indicated vaccines. These data are pooled from three
independent experiments with 3–5 mice per group in each experiment. (**) indicates p,0.0001, (*) indicates p,0.05. Unless otherwise stated, live
virus vaccinations are compared to vaccination with reovirus, and VRP vaccinations are compared to HA VRP. LD indicates the limit of detection.
doi:10.1371/journal.ppat.1000236.g003
Mechanims of Norovirus Immunity
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important for efficient clearance of MNV infection in both the
MLN and distal ileum, and they function later in infection than
CD4 T cells, being most important at days six and seven.
Function of CD4 and CD8 T Cells from Immunized Mice
We next determined whether CD4 and CD8 T cells from
vaccinated mice can, alone or in combination, clear MNV
infection from mucosal sites. We have previously shown that MNV
infected RAG1-/- mice have high levels of viral RNA present in
multiple tissues up to 90 days post-infection [27]. We therefore
determined MNV viral titers in RAG1-/- mice. By 42 days post-
infection, all RAG1-/- mice had consistent, high levels of MNV in
both duodenum/jejunum and distal ileum (Figure 6A and 6B), as
well as several other tissues (data not shown). These data
confirmed that mice lacking adaptive immunity fail to clear
MNV infection [27].
The availability of persistently infected RAG1-/- mice allowed
us to determine the role of CD4 and CD8 T cells in clearance of
MNV infection using adoptive transfer of splenocytes from MNV
immune WT mice into persistently infected RAG1-/- mice.
Transfer of immune, but not non-immune, splenocytes signifi-
Figure 4. MHC Class II limits early MNV replication, and deficiency in MHC Class II or MHC Class I & b2M delays MNV clearance. (A)
Protocol of challenge used in experiments in this figure. Viral titers in distal ileum (B,D) and MLN (C,E) of WT and MHC Class I6b2M-/- mice (B,C) and
MHC Class II-/- mice (D,E) after infection with MNV1.CW3. These data are pooled from two to three independent experiments with 3–5 mice per
group in each experiment. (**) indicates p,0.0001, (*) indicates p,0.05. LD indicates the limit of detection.
doi:10.1371/journal.ppat.1000236.g004
Mechanims of Norovirus Immunity
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and distal ileum (p,0.0001) six days post-transfer (Figure 7B and
7C). Thus, adoptively transferred immune splenocytes were
sufficient to clear persistent MNV infection in the intestine of
RAG1-/- mice.
To define which cells were required for MNV clearance, CD4 or
CD8 T cells were depleted from splenocytes transferred into
RAG1-/- recipients. Anti-T cell antibodies effectively depleted the
appropriate T cell populations, as measured six days post-transfer by
flow cytometry (Figure 7A). Depletion of either CD4 or CD8 T cells
individually led to a significant increase in MNV titers in
duodenum/jejunum compared to control depletion (Figure 7B,
CD4 depletion p=0.0042; CD8 depletion p=0.0002). Depletion of
both CD4 and CD8 T cells from transferred immune splenocytes
caused a significant additional increase in MNV titers when
comparedtoeitherCD4 depletionalone (p=0.02)orCD8depletion
alone (p=0.03). In the distal ileum, depletion of either CD4 T cells
(p=0.0003) or CD8 T cells (p,0.0001) led to a significant increase
in MNV titers (Figure 7C). These data demonstrated that both
immune CD4 and CD8 T cells were necessary for clearance of
persistent MNV infection from the intestine.
Perforin Has a Role in Clearance of MNV Infection
Two major effector mechanisms for the antiviral effects of T
cells are the production of IFNc and perforin mediated cytolysis
[49]. We therefore adoptively transferred immune splenocytes
from IFNc-/- or perforin-/- mice into persistently infected
Figure 5. CD4 and CD8 T cells are required for clearance of
primary MNV infection at 6 days post-infection. (A) Representative
flowcytometricanalysisofCD4andCD8stainingonsplenocytesharvested
from control and immunodepleted WT mice 6 days post-infection with
MNV1.CW3. Viral titer in (B) distal ileum and (C) MLN after treatment with
the indicated antibodies. Results are pooled from two independent
experiments with 3–5 mice per group in each experiment. (**) indicates
p,0.0001, (*) indicates p,0.05. LD indicates the limit of detection.
doi:10.1371/journal.ppat.1000236.g005
Figure 6. RAG1-/- mice fail to clear MNV infection in the
intestine. Viral titers in (A) duodenum/jejunum and (B) distal ileum of
RAG1-/- mice after infection with MNV1.CW3. Results are pooled from
four independent experiments with 5 mice per group in each
experiment. LD indicates the limit of detection.
doi:10.1371/journal.ppat.1000236.g006
Mechanims of Norovirus Immunity
PLoS Pathogens | www.plospathogens.org 8 December 2008 | Volume 4 | Issue 12 | e1000236Figure 7. Immune CD4 and CD8 T cells are both required, and perforin plays a role in clearance of persistent MNV infection in
RAG1-/- recipients. (A) Representative flow cytometric analysis of splenocytes harvested from RAG1-/- recipient mice 6 days post-transfer of
splenocytes. Viral titers in (B) duodenum/jejunum and (C) distal ileum 6 days after adoptive transfer of medium alone, WT non-immune splenocytes
(N–I), WT immune splenocytes (WT), WT immune splenocytes with or without depleting antibodies or immune splenocytes from IFNc-/- or perforin-/-
(Pfn-/-) mice. These data are pooled from three independent experiments with 3–5 mice per group in each experiment. (**) indicates p,0.0001, (*)
indicates p,0.05. LD indicates the limit of detection.
doi:10.1371/journal.ppat.1000236.g007
Mechanims of Norovirus Immunity
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MNV infection. Immune splenocytes from IFNc-/- mice were as
effective as those from WT mice (Figure 7B and 7C). However,
immune splenocytes from perforin-/- mice were less effective at
clearing MNV infection from the duodenum/jejunum (p=0.0003,
Figure 7C) or distal ileum (p=0.0075, Figure 7B) than cells from
either WT or IFNc-/- mice, but more effective compared to
transfer of non-immune cells in duodenum/jejunum (p=0.0086)
or distal ileum (p=0.0001). Thus, while perforin was critical for
efficient clearance of MNV infection from the intestine, it was not
the only relevant effector mechanism.
Discussion
In this paper we define the mechanisms of immunity to
norovirus infection as measured by both vaccination against, and
clearance of, mucosal infection. We found that it is possible to
generate highly effective, and remarkably long lasting, immunity
to norovirus infection by oral exposure to live virus. Further,
systemic exposure to the viral capsid protein expressed in a vaccine
vector resulted in effective immunity, albeit not as effective as that
observed after live virus vaccination. Importantly, this shows that
the MNV VP1 protein contains relevant B cell, CD4 T cell and
CD8 T cell epitopes. Vaccination was effective in aged mice.
Additionally, vaccination in adult mice required the concerted
action of CD4 T cells, CD8 T cell, and B cells to be completely
protective in the tissues surveyed. Interestingly, the activities of
different components of the adaptive immune system in clearance
and vaccination were tissue specific, with different cells playing
roles in the intestine itself compared to the draining lymph nodes.
Perforin was an important effector molecule. These data have
important implications for understanding adaptive immunity to an
animal norovirus, representative of a genus that causes significant
disease in humans.
HuNV infection and disease is rapid, with symptoms developing
within 24–48 hours of infection and lasting for a few days. Thus,
we selected three days after challenge as a readout for infection in
our studies, since relevant vaccine-generated immune responses
would have to act very early after challenge. Lack of any of the
three components of the adaptive response: B cells, CD4 T cells, or
CD8 T cells significantly diminished vaccine effects generated by
either live virus or VP1 capsid protein immunization, and delayed
viral clearance during primary infection. This indicates that VP1
has antibody epitopes as well as MHC H-2b restricted CD4 and
CD8 T cell epitopes. These data suggest that it may be necessary
to engage the concerted actions of an intact immune response
including both MHC Class I and MHC Class II restricted T cells
and antibody responses to efficiently vaccinate against HuNV
infection.
The protection against MNV infection in aged mice in the
absence of robust generation of anti-MNV antibodies raised the
possibility that an important component of the vaccine response is
T cell dependent, a hypothesis borne out in adoptive transfer
studies. Importantly, the antiviral effector perforin is important in
the clearance of MNV from the intestine, suggesting that the
cytotoxic T cell response is a key effector mechanism. It is possible
that other cell types such as NK cells might also use perforin as a
mechanism to control MNV infection. Our data do not rule out a
role for IFNc in clearance of MNV infection since NK cells in
recipient RAG1-/- mice can make IFNc, but do suggest that T cell
derived IFNc plays at most a minor role in effector T cell function
in the ileum. This argues that classical CTL assays may be a good
surrogate for the development of effective vaccine-generated
immune responses to HuNV.
Live virus vaccination was more effective than VRP based
vaccination. The lower level of protection that we observed with
ORF2 VRPs in contrast to MNV1.CW3 may be due to many
factors, and this study does not provide mechanistic insights into
this difference. In comparison to VLPs, VRPs may have
advantages in systemic vaccination including targeting dendritic
cells and intrinsic adjuvant activities [50]. These properties of
VRPs may be responsible for the effectiveness of systemic single
protein subunit vaccination against mucosal viral challenge in this
case. However, it may be that because VRPs undergo a single
round of replication at the site of inoculation they cannot generate
the same breadth of immunity that is generated by live replicating
virus. While VRP vaccination clearly induces some relevant
effector and memory cell responses, vaccination with capsid alone
may not sufficient to generate the complete antigenic repertoire
required for effective immunity. Interestingly, we found some
protection with the non-structural ORF1 polyprotein, suggesting
that protective epitopes exist outside of the capsid protein. As the
ORF1 polyprotein is expressed early after infection, it may be that
these epitopes would be valuable targets for generating an efficient
immune response.
Of note, vaccination with VP1 via the subcutaneous route
provided significant protection despite the fact that the vaccination
occurred systemically, while protection was read out at a mucosal
site. This indicates that an active systemic immune response can
provide protection against norovirus infection, and a mucosal
vaccine may not be necessary to vaccinate against norovirus
infection. Importantly, systemic vaccination was dependent on T
cells, indicating that the relevant cells can traffic to the intestine
after peripheral VRP-based vaccination.
These studies leave several important questions unanswered.
Firstly, we used a homologous virus challenge. In nature, it is likely
that hosts are repeatedly challenged with antigenically distinct
noroviruses. However, the mouse norovirus strains identified so far
fall into a single genogroup, GV, which likely represents a single
serotype [9]. In this way murine noroviruses identified to date may
present less of a challenge for the immune system than HuNV,
which are distributed across 3 genogroups and appear to evolve
under antibody selection [51]. In addition, we selected a strain of
MNV that is cleared by WT mice. Other strains persist for
prolonged periods of up to 35 days [9]. It remains to be
determined whether vaccination will be effective against persistent
MNV strains. It is interesting that human noroviruses can persist
beyond the time frame of usual clinical symptoms [52–55]. Long-
term persistence might contribute to explaining the sporadic
epidemics of infection in the absence of an animal reservoir.
Antigenic and pathogenetic complexity will likely be a major issue
for the development of norovirus vaccines. The lack of comparable
variation in MNV strains limits the utility of the MNV model for
assessing immunity to antigenically distinct strains. Perhaps this
limitation will be overcome as additional strains of MNV are
identified, sequenced, and studied. However, the fact that we
observed partial cross protection between MNV and one HuNV,
and the demonstration that vaccination with many different VLPs
can enhance generation of cross reactive antibodies [56] provide
some encouragement.
There are two ways in which murine norovirus infection may
not represent the same biology as HuNV infection. The first is the
lack of diarrhea in mice infected with the strains of MNV used
here. It is possible that the adaptive responses that clear MNV
from the intestine demonstrated here are irrelevant to the
responses that may prevent human disease. In this regard, it is
important to note that studies of adult mice with rotaviruses (also
an infection only model), have been important to our consider-
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not reveal the mechanisms of effective immunity and are based on
surrogate assays of immunity, since invasive sampling of tissues
may be technically difficult. Studies in piglets may be revealing
since piglets develop diarrhea when infected with the HuNV
strain, HuNoV-HS66 [37]. However, it is more difficult to study
immune mechanisms in this system. Thus, we are left with several
imperfect systems for considering what one should seek in a
HuNV vaccine. Our studies in mice argue for a vaccine that
induces all aspects of the adaptive immune response, and that
assays for cytotoxic lymphocyte responses to HuNV infection may
be an important surrogate assay for protection.
The second aspect of murine norovirus infection that is of
unknown relevance to human infection is the impressive capacity
of MNV to infect lymph nodes draining the intestine (this paper
and [31,58,59]). This may be related to the tropism of MNV for
dendritic cells and macrophages [28,59] and likely reflects spread
of MNV directly from the intestine, but may also reflect seeding of
the MLN from systemic sites. Considering the distal ileum alone, B
cells and MHC Class I and b2M were not required for live virus
vaccination, and there was significant, but incomplete, protection
in MHC Class II-/- mice (Figure 3B and 3C). Consistent with this,
studies of primary clearance showed that any single arm of the
adaptive response was dispensable for ultimate control of primary
infection in the intestine. However, vaccination-mediated control
of infection in the MLN, and clearance of primary infection from
the MLN [39], required B cells. This differential requirement for
components of the immune response in different organs raises an
important question about norovirus pathogenesis and lymphoid
infection: are the cells infected in intestine and MLN the same?
Differences in viral tropism in the two tissues might explain the
differential requirement for B cells between ileum and MLN,
indicating the importance of future studies on the role of immunity
in norovirus cell and organ tropism.
Materials and Methods
Viruses, Viral Stocks, VRPs, Plaque Assays
MNV strains MNV1.CW3 or MNV1.CW1 were used in all
virus infections [9,28,31]. Two mutations (that result in changes in
the encoded amino acids) distinguish the genomes of MNV1.CW3
and MNV1.CW1 [28]. To generate a concentrated virus stock,
RAW 264.7 cells (ATCC, Manassas, VA) were infected in VP-
SFM media (Gibco, Carlsbad, CA) for 2 days at a multiplicity of
infection (MOI) of 0.05. Supernatants were clarified by low-speed
centrifugation for 20 min at 3,000 rpm. Virus was concentrated
by centrifugation at 4uC for 3 h at 27,000 rpm (90,000 g)i na
SW32 rotor. Viral pellets were resuspended in PBS and titered on
RAW 264.7 cells as previously described [28]. Type I Lang
reovirus was kindly provided by Dr. Terrence S. Dermody
(Vanderbilt University, Nashville, TN). Plaque assays were
performed as previously described [28] with the following
modifications. Tissues were harvested into sterile, screw-top 2-ml
tubes containing 500 ml of 1-mm zirconia/silica beads (BioSpec
Products, Bartlesville, OK) and stored at 280uC. To obtain viral
titers in these tissues 1 ml of complete DMEM was added to each
sample on ice and homogenized using a MagNA Lyser (Roche
Applied Science, Hague Road, IN) prior to plaque assay. The limit
of detection was 20 plaque forming units (PFU)/ml.
All VRPs were produced as previously described [60]. Briefly,
ORFs 1, 2 and 3 from MNV1.CW3 and ORF2 from Lordsdale
virus and Chiba virus were each cloned into VRP expression
vectors. Following infection of BHK cells with VRPs for 24 h,
culture supernatants were harvested and cells lysed. Proteins were
separated by SDS-PAGE and analyzed by western blot with
polyclonal rabbit anti-MNV serum [28]. VRP titers and efficient
expression of recombinant protein were determined by immuno-
fluorescence assay using mouse antisera generated from inocula-
tion with respective antigens. Cell lysates from MNV ORF2,
Chiba virus and Lordsdale virus VRP-infected cell cultures were
further purified to obtain VLPs [56].
Cell Cultures and Antibodies
RAW 264.7 cells were maintained as previously described [28].
Monoclonal antibodies (MAbs) specific to CD4 (YTS191.1 [61]),
CD8 (H35 [62]) and SFR3-DR5 (ATCC HB-151 [63]) were
produced from hybridoma cell lines in INTEGRA Celline CL1000
flasks (Integra Biosciences, Ijamsville, MD) using CD Hybridoma
media (Gibco, Carlsbad, CA) as previously described [64].
Mice, Inoculations, and Infections
All mice were bred and housed at Washington University School
of Medicine or the University of North Carolina at Chapel Hill in
accordance with all federal and university policies. Wild type
C57BL6/J (hereafter referred to as WT, Jackson # 000664),
B6RAG1-/- (RAG1-/-, Jackson # 002216), IFNc-/- (IFNc-/- ,
Jackson # 002287), perforin-/- (perforin-/-, Jackson # 002407),
MHC Class II-/- (MHC Class II-/-, Jackson #003584) and B-cell-
deficient mice backcrossed onto a C57BL/6 background (B cell-/-,
Jackson # 002288) mice were purchased from Jackson Laboratory
(Bar Harbor, ME). MHC Class II deficient mice (MHC Class II-/-,
Taconic #ABBN12-M) and their WT controls C57BL/6Ntac (WT,
B6 Taconic) were purchased from Taconic (Germantown, NY).
K
b2/26D
b2/26b2M-/- [43] (MHC Class I6b2M-/-) mice were a
generous gift of Dr. Ted Hansen (Washington University, St Louis,
MO). For some studies, WT C57BL6/J mice were purchased from
Harlan Sprague Dawley (Indianapolis, IN) and aged to 14 months.
All mice (or cage sentinel mice for mice deficient in antibody
production) were tested by ELISA for the presence of MNV
antibody prior to experiments [27]. All mice used in these studies
were seronegative at the initiation of experiments.
Mice used in vaccination studies were immunized with 3610
7
PFU of MNV1.CW1 [28], MNV1.CW3 [31], or control Type I
Lang reovirus per orally (p.o.) in 25 ml of DMEM containing 10%
fetal bovine serum (Hyclone, Logan, UT) (cDMEM). VRP
immunizations were with 2.5610
6 infectious units (IU) of each
VRP expressing MNV1.CW3 ORF1, ORF2, or ORF3 individ-
ually or in groups of 2–3 VRPs; Chiba virus ORF2 or Lordsdale
virus ORF2 in 10 mlo r5 0ml volume by footpad inoculation (into
the subcutaneous space) [65] on day 0 and boosted on day 21. HA
VRP and PBS immunizations in 10 mlo r5 0ml volume by footpad
inoculation [65] on day 0 and boosted on day 21 served as controls
for all VRP immunizations. Mice were challenged with 3610
7
PFU of MNV1.CW3 at specified times after boost and tissues
harvested three days post-challenge. Controls for VRP vaccination
included PBS or VRPs expressing hemagglutinin (HA) from a
mouse adapted influenza A virus [41]. PBS served as a control for
HA VRP in these experiments in the event that HA VRP had a
significant effect on MNV replication. HA VRP controls were not
significantly different from PBS controls in all experiments and
both are presented in all figures for completeness.
RAG1-/- and all splenocyte donor mice were infected with
3610
6 PFU of MNV1.CW3 p.o. in 25 ml of cDMEM. All other
mice were infected with 3610
7 PFU MNV1.CW3 p.o. In
RAG1-/- mice two segments of the small intestine were harvested:
a one inch section of the small intestine immediately distal to the
pylorus of the stomach, (designated the duodenum/jejunum), and
a one inch section of the small intestine immediately proximal to
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ileum and three mesenteric lymph nodes (MLN) were harvested.
With the exception of RAG1-/- mice (inoculated at 4–6 weeks of
age) and aged WT mice (inoculated at 14 months of age), all other
mice were inoculated at 6–10 weeks of age.
Adoptive Transfer Studies
Spleens were harvested from mice and single cell suspensions
were generated [65]. Cells were counted and diluted in RPMI-
1640 media (Sigma, Saint Louis, MO) supplemented with 10%
fetal calf serum (HyClone, Logan, UT), 100 U penicillin/ml,
100 mg/ml streptomycin, 10 mM HEPES (N-2-hydroxyethylpi-
perazine-N9-2-ethanesulfonic acid), 1mM sodium pyruvate,
50 mM 2-mercaptoethanol and 2 mM L-glutamine (cRPMI). In
all adoptive transfer experiments, 1610
7 cells were injected into
persistently infected RAG1-/- mice by intraperitoneal (i.p.)
injection in 0.5ml cRPMI.
In Vivo Depletion of Lymphocyte Subsets
For depletions in WT mice, 500 mg of lymphocyte-depleting
antibody or an isotype-matched control antibody [SFR3-DR5,
IgG2b] was administered i.p. one day prior and one day after
infection. For depletions in adoptive transfer experiments,
depleting antibodies were administered to RAG1-/- recipients as
described above with one dose one day prior to splenocyte transfer
and a second dose on the day of trnsfer. The efficacy of
lymphocyte depletion in both sets of depletion experiments was
monitored by flow cytometric analysis of splenocytes at the end of
the experiment.
MNV ELISA
ELISA to detect binding of polyclonal anti-serum or fecal
extract-derived antibody to purified MNV virions or MNV VLPs
was performed as previously described [27,56].
Statistical Methods
All data were analyzed using GraphPad Prism software
(GraphPad Software, San Diego, CA). Viral titer data were
analyzed with the nonparametric Mann-Whitney test. All
differences not specifically stated to be significant were insignif-
icant (p.0.05).
Supporting Information
Figure S1 VRP protein expression and serum IgG responses in
immunized mice. (A) Western blots showing MNV protein
expression from culture supernatants and cell lysates of BHK
cells infected with VRPs expressing MNV1.CW3 ORF1, ORF2,
or ORF3; Chiba virus (CV) and Lordsdale virus (LV) VLPs were
analyzed for cross-reactivity with MNV rabbit polyclonal antisera.
VRP-ORF1 infected cells revealed a band corresponding in size to
the cleaved RNA-dependent RNA polymerase (57 kDa). VRP-
ORF2 infected cell lysate and supernatant both contained capsid
protein at high expression levels (58 kDa), and VRP-ORF3
infected cell lysates contained a band corresponding in size to
ORF3 (22 kDa) [28,40]. Purified MNV VLPs from cell lysates
yielded a single 57 kDa band corresponding to the capsid. (B) Sera
from mice immunized with VRPs expressing ORF2 from
MNV1.CW3, Chiba virus (CV), or Lordsdale virus (LV) were
tested for cross-reactivity to MNV1.CW3, CV, and LV VLPs by
ELISA. (C) Serum anti-MNV antibody by ELISA from adult (8
week old) and aged (14 month old) mice after MNV1.CW3
challenge. These data are pooled from two independent
experiments with 3–5 mice per group in each experiment.
Found at: doi:10.1371/journal.ppat.1000236.s001 (2.77 MB TIF)
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